亞邦絲醫療 INVA 深 滬
已收盤 02-06 16:00:00 美东时间
21.80
+0.230
+1.07%
華盛通- 最 高21.92
- 今 開21.56
- 成交量 65.06万股
- 最 低 21.56
- 昨 收 21.57
- 總市值 16.30亿
- 52周最高 22.76
- 市盈率 靜 60.20
- 換手率 0.87%
- 52周最低 16.52
- 委 比 45.56%
- 總股本 7476.91万
- 歷史最高 41.96
- 量 比 0.67
- 振 幅 1.67%
- 歷史最低 6.36
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Cantor Fitzgerald Maintains Overweight on Innoviva, Raises Price Target to $31
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and raises the price target from $29 to $31.
2025-11-06 22:42
Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.52 by 109.71 percent. This is a 5300 percent increase over earnings of $0.02 per share from the same
2025-11-06 05:47
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
2025-10-01 20:13
Goldman Sachs Initiates Coverage On Innoviva with Sell Rating, Announces Price Target of $17
Goldman Sachs analyst Asad Haider initiates coverage on Innoviva (NASDAQ:INVA) with a Sell rating and announces Price Target of $17.
2025-09-30 21:06
HC Wainwright & Co. Maintains Buy on Innoviva, Raises Price Target to $45
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price target from $40 to $45.
2025-08-11 18:41
